v3.19.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 13,828,206 $ 22,154,251
Short-term investments 5,648,609 5,570,027
Accounts receivable 77,382 28,538
Prepaid expenses and other current assets 684,169 961,317
Total Current Assets 20,238,366 28,714,133
Property and Equipment, net 566,593 643,146
Other Assets    
In-process R&D 5,866,000 5,866,000
Goodwill 2,189,338 2,189,338
Right-of-use asset 406,178
Deposits 436,283 351,220
Total Other Assets 8,897,799 8,406,558
Total Assets 29,702,758 37,763,837
Current Liabilities    
Accounts payable 1,979,090 974,619
Deferred revenue 1,032,539
Contingent consideration, current portion 1,222,000 1,187,000
Operating lease liability, current portion 129,205
Accrued expenses and other liabilities 1,169,609 1,678,051
Total Current Liabilities 4,499,904 4,872,209
Long Term Liabilities    
Contingent consideration 2,109,515 1,918,225
Deferred tax liability 361,911 316,733
Deferred revenue, net of current portion 200,000 200,000
Operating lease liability, net of current portion 282,353
Other long-term liabilities 293,582 213,724
Total Liabilities 7,747,265 7,520,891
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 34,066,652 and 32,492,144 shares issued and outstanding at June 30, 2019 (unaudited) and December 31, 2018, respectively 6,822 6,499
Additional paid-in capital 117,350,922 114,883,135
Accumulated deficit (95,066,526) (84,580,180)
Accumulated other comprehensive loss (11,481) (19,904)
Total Stockholders' Equity-Heat Biologics, Inc. 22,279,737 30,289,550
Non-Controlling Interest (324,244) (46,604)
Total Stockholders' Equity 21,955,493 30,242,946
Total Liabilities and Stockholders' Equity $ 29,702,758 $ 37,763,837

Source